Led by OrbiMed, with participation from RA Capital Management, Janus Henderson Investors, Sanofi Ventures, Harbour BioMed, and existing investors ...

Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued ...

Moby Strategic Execution and Market Dynamics. Performance in Q1 was characterized by a significant shift in patient mix, with ...

Q1 2026 Management View Dr. David Hung said the launch is being driven by steady demand and an improving mix toward earlier-line use: “We successfully treated approximately 200 new patients with ...

The Bay Area born agtech company has been beefing up its local research presence and already has a manufacturing facility in the region.

For this action, the firm cited the potential of Nuvation Bio’s glioma drug candidate, safusidenib. First, RBC Capital ...

Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching curative targeted cell therapies designed ...